Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee test could spot colon cancer early in africa

NCT ID NCT07649057

Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new urine test that aims to detect colorectal cancer and precancerous polyps early. Researchers will enroll 210 people in Ghana, Tanzania, and South Africa who have symptoms like rectal bleeding or are getting a colonoscopy. The test uses a biosensor to find three specific substances in urine, and the goal is to see if it works as well as earlier results from Nigeria, which showed 90% accuracy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3-metabolite biosensor (urine test)
What this could lead to
If successful, this could provide a simple, non-invasive urine test for early detection of colorectal cancer in Africa, improving survival rates.
What could go wrong
This is a validation study in specific African regions; results may not generalize elsewhere. The test's accuracy may be lower than hoped, and it is not yet a standard screening tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Data and samples will be collected from 3 sites in Africa: Korle Bu Teaching Hospital/University of Ghana Medical School in Ghana; Kilimanjaro Christian Medical Centre in Tanzania and Wits Donald Gordon Medical Centre, Wits Donald Gordon Medical Research Institute in South Africa. Consent will occur at these sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient presents with one of the following: * Patients with symptoms of CRC (such as rectal bleeding for a week) -OR- * Patients who present for a screening colonoscopy -OR- * Has received one of the following within 3 weeks of the planned urine collection * Patients with a pathologic diagnosis of CRC either by colonoscopy or resection specimens -OR- * Patients with colonoscopy demonstrating adenomatous polyps -OR- * Patients with colonoscopy demonstrating no colon or premalignant or malignant pathology * Age ≥ 18 * Willingness to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm Gastrointestinal Hemorrhage precancerous condition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer CRC Precancerous polyp Rectal bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kilimanjaro Christian Medical Centre (Data Collection Only)

    NOT_YET_RECRUITING

    Moshi, Tanzania

  • Korle Bu Teaching Hospital (Data Collection Only)

    NOT_YET_RECRUITING

    Accra, Ghana

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Wits Donald Gordon Medical Centre (Data Collection Only)

    NOT_YET_RECRUITING

    Johannesburg, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.